Cargando…

Clinical Significance and Role of Lymphatic Vessel Invasion as a Major Prognostic Implication in Non-Small Cell Lung Cancer: A Meta-Analysis

BACKGROUND: Lymphatic vessel invasion (LVI) exerts an important process in the progression and local spread of cancer cells. However, LVI as a prognostic factor for survival in non-small cell lung cancer (NSCLC) remains controversial. METHODOLOGY/PRINCIPAL FINDINGS: A meta-analysis of published stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jun, Wang, Baocheng, Zhao, Weipeng, Guo, Yan, Chen, Hong, Chu, Huili, Liang, Xiuju, Bi, Jingwang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527568/
https://www.ncbi.nlm.nih.gov/pubmed/23285161
http://dx.doi.org/10.1371/journal.pone.0052704
_version_ 1782253752269406208
author Wang, Jun
Wang, Baocheng
Zhao, Weipeng
Guo, Yan
Chen, Hong
Chu, Huili
Liang, Xiuju
Bi, Jingwang
author_facet Wang, Jun
Wang, Baocheng
Zhao, Weipeng
Guo, Yan
Chen, Hong
Chu, Huili
Liang, Xiuju
Bi, Jingwang
author_sort Wang, Jun
collection PubMed
description BACKGROUND: Lymphatic vessel invasion (LVI) exerts an important process in the progression and local spread of cancer cells. However, LVI as a prognostic factor for survival in non-small cell lung cancer (NSCLC) remains controversial. METHODOLOGY/PRINCIPAL FINDINGS: A meta-analysis of published studies from PubMed and EMBASE electronic databases was performed to quantity the effects of LVI on both relapse-free survival and overall survival for patients with NSCLC. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were used to assess the strength of these effects. This meta-analysis included 18,442 NSCLC patients from 53 eligible studies. LVI appeared in 32.1% (median; range, 2.8% to 70.9%) of tumor samples. In all, patients with LVI were 2.48 times more likely to relapse by univariate analysis (95% CI: 1.92–3.22) and 1.73 times by multivariate analysis (95% CI: 1.24–2.41) compared with those without LVI. For the analyses of LVI and overall survival, the pooled HR estimate was 1.97 (95% CI: 1.75–2.21) by univariate analysis and 1.59 (95% CI: 1.41–1.79) by multivariate analysis. Multivariate analysis showed a risk was 91% higher for recurrence (HR  = 1.91, 95% CI: 1.14–2.91) and 70% higher for mortality (HR = 1.70, 95% CI: 1.38–2.10) in LVI-positive I stage patients compared with LVI-negative I stage patients. Subgroup analyses showed similar significant adjusted risks for recurrence and death in adenocarcinomas, and a significant adjusted risk for death in studies that utilized elastic staining with or without immunohistochemistry in defining LVI. CONCLUSIONS/SIGNIFICANCE: The present study indicates that LVI appears to be an independent poor prognosticator in surgically managed NSCLC. NSCLC patients with LVI would require a more aggressive treatment strategy after surgery. However, large, well-designed prospective studies with clinically relevant modeling and standard methodology to assess LVI are required to address some of these important issues.
format Online
Article
Text
id pubmed-3527568
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35275682013-01-02 Clinical Significance and Role of Lymphatic Vessel Invasion as a Major Prognostic Implication in Non-Small Cell Lung Cancer: A Meta-Analysis Wang, Jun Wang, Baocheng Zhao, Weipeng Guo, Yan Chen, Hong Chu, Huili Liang, Xiuju Bi, Jingwang PLoS One Research Article BACKGROUND: Lymphatic vessel invasion (LVI) exerts an important process in the progression and local spread of cancer cells. However, LVI as a prognostic factor for survival in non-small cell lung cancer (NSCLC) remains controversial. METHODOLOGY/PRINCIPAL FINDINGS: A meta-analysis of published studies from PubMed and EMBASE electronic databases was performed to quantity the effects of LVI on both relapse-free survival and overall survival for patients with NSCLC. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were used to assess the strength of these effects. This meta-analysis included 18,442 NSCLC patients from 53 eligible studies. LVI appeared in 32.1% (median; range, 2.8% to 70.9%) of tumor samples. In all, patients with LVI were 2.48 times more likely to relapse by univariate analysis (95% CI: 1.92–3.22) and 1.73 times by multivariate analysis (95% CI: 1.24–2.41) compared with those without LVI. For the analyses of LVI and overall survival, the pooled HR estimate was 1.97 (95% CI: 1.75–2.21) by univariate analysis and 1.59 (95% CI: 1.41–1.79) by multivariate analysis. Multivariate analysis showed a risk was 91% higher for recurrence (HR  = 1.91, 95% CI: 1.14–2.91) and 70% higher for mortality (HR = 1.70, 95% CI: 1.38–2.10) in LVI-positive I stage patients compared with LVI-negative I stage patients. Subgroup analyses showed similar significant adjusted risks for recurrence and death in adenocarcinomas, and a significant adjusted risk for death in studies that utilized elastic staining with or without immunohistochemistry in defining LVI. CONCLUSIONS/SIGNIFICANCE: The present study indicates that LVI appears to be an independent poor prognosticator in surgically managed NSCLC. NSCLC patients with LVI would require a more aggressive treatment strategy after surgery. However, large, well-designed prospective studies with clinically relevant modeling and standard methodology to assess LVI are required to address some of these important issues. Public Library of Science 2012-12-20 /pmc/articles/PMC3527568/ /pubmed/23285161 http://dx.doi.org/10.1371/journal.pone.0052704 Text en © 2012 Wang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Wang, Jun
Wang, Baocheng
Zhao, Weipeng
Guo, Yan
Chen, Hong
Chu, Huili
Liang, Xiuju
Bi, Jingwang
Clinical Significance and Role of Lymphatic Vessel Invasion as a Major Prognostic Implication in Non-Small Cell Lung Cancer: A Meta-Analysis
title Clinical Significance and Role of Lymphatic Vessel Invasion as a Major Prognostic Implication in Non-Small Cell Lung Cancer: A Meta-Analysis
title_full Clinical Significance and Role of Lymphatic Vessel Invasion as a Major Prognostic Implication in Non-Small Cell Lung Cancer: A Meta-Analysis
title_fullStr Clinical Significance and Role of Lymphatic Vessel Invasion as a Major Prognostic Implication in Non-Small Cell Lung Cancer: A Meta-Analysis
title_full_unstemmed Clinical Significance and Role of Lymphatic Vessel Invasion as a Major Prognostic Implication in Non-Small Cell Lung Cancer: A Meta-Analysis
title_short Clinical Significance and Role of Lymphatic Vessel Invasion as a Major Prognostic Implication in Non-Small Cell Lung Cancer: A Meta-Analysis
title_sort clinical significance and role of lymphatic vessel invasion as a major prognostic implication in non-small cell lung cancer: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527568/
https://www.ncbi.nlm.nih.gov/pubmed/23285161
http://dx.doi.org/10.1371/journal.pone.0052704
work_keys_str_mv AT wangjun clinicalsignificanceandroleoflymphaticvesselinvasionasamajorprognosticimplicationinnonsmallcelllungcancerametaanalysis
AT wangbaocheng clinicalsignificanceandroleoflymphaticvesselinvasionasamajorprognosticimplicationinnonsmallcelllungcancerametaanalysis
AT zhaoweipeng clinicalsignificanceandroleoflymphaticvesselinvasionasamajorprognosticimplicationinnonsmallcelllungcancerametaanalysis
AT guoyan clinicalsignificanceandroleoflymphaticvesselinvasionasamajorprognosticimplicationinnonsmallcelllungcancerametaanalysis
AT chenhong clinicalsignificanceandroleoflymphaticvesselinvasionasamajorprognosticimplicationinnonsmallcelllungcancerametaanalysis
AT chuhuili clinicalsignificanceandroleoflymphaticvesselinvasionasamajorprognosticimplicationinnonsmallcelllungcancerametaanalysis
AT liangxiuju clinicalsignificanceandroleoflymphaticvesselinvasionasamajorprognosticimplicationinnonsmallcelllungcancerametaanalysis
AT bijingwang clinicalsignificanceandroleoflymphaticvesselinvasionasamajorprognosticimplicationinnonsmallcelllungcancerametaanalysis